



In 2025, the FDA approved 26 novel therapies and the EMA approved 16 specifically for rare diseases




Global first launch in rare disease by TA



Global first launch in a rare disease by technology



The rare-disease pipeline is more diverse than ever, with sustained growth across early- and late-stage development reflecting scientific progress



Source: Evaluate Pharma March 2026